HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
AIM ImmunoTech Inc. (AIM)
2.43  -0.01  (-0.41%) 07-03 16:55
Open: 2.4 High: 2.44
Pre.close: 2.44 Low: 2.36
Volume: 1,719,091 Ave vol: 3,786,484
52w High: 7.11 52w Low: 0.38
MA(50): 2.531 MA(200): 1.856
EPS: -5.873 P/E Ratio: 0
Company profile
Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aimimmuno.com
Market Cap (M): 79
Shares Out (M): 33
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine.
Technical analysis
Overall: Underperform
MA: Bearish MACD: Bearish
KDJ: Bearish RSI: Bearish
Target 1: 3.11 Target 2: 3.47
Resist 1: 2.66 Resist 2: 2.97
Support 1: 2.16 Support 2: 1.80
Company key metrics
Revenue per Share: 0.0384
Net Income per Share: -2.617
Cash per Share: 0.4035
Book Value per Share: 3.5432
Price to Sales: 26.2796
Price to Book Value: 0.2851
Earnings Yield: -2.5911
Dividend Yield: 0
Debt to Equity: 0.5665
Debt to Assets: 0.3616
Financial analysis
Price to Book Value: Outperform
Return on Assets: Neutral
Return on Equity: Underperform
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Neutral
Stock Charts
Headline news
Fri, 26 Jun 2020
Why AIM ImmunoTech Inc. (AIM) Shares Are Shooting Higher After Recent Events - The News Heater

Fri, 03 Jul 2020
AIM ImmunoTech Inc. (AIM) is predicted to post EPS of -0.10 in the upcoming quarter : This Stock is Ticking Every Box for Top Investors - News Daemon

Fri, 26 Jun 2020
AIM ImmunoTech Inc. (AMEX:AIM) is Waving the Bull Flag - The Oracle Dispatch

Wed, 10 Jun 2020
Here's a Way to Trade AIM ImmunoTech Inc. (AIM) - The News Heater

Tue, 16 Jun 2020
Buy or Sell AIM ImmunoTech Inc. (AIM) Stock Now? Don't Try to Be a Top Gun - The News Heater

Thu, 11 Jun 2020
AIM ImmunoTech files provisional patent application for Ampligen as treatment for COVID-19 induced fatigue - Proactive Investors USA & Canada

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.